Results 51 to 60 of about 47,341 (232)
Zuranolone: A case study in (regulatory) rush to judgement?
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
Sertraline use in pregnancy and placental transfer: A pharmacokinetic prospective cohort study
Introduction Depression in pregnancy is common and the use of antidepressants in pregnancy, especially sertraline, is on the rise. Although sertraline is known to cross the placenta, the level of transfer to the foetus is unclear.
Charlotte Goutallier +8 more
doaj +1 more source
Sertraline demonstrates fungicidal activity in vitro for Coccidioides immitis
Coccidioidomycosis causes substantial morbidity in endemic areas. Disseminated coccidioidomycosis is an AIDS defining condition and treatment often requires lifelong antifungal therapy.
Simon Paul +2 more
doaj +1 more source
Assessment of a method to detect signals for updating systematic reviews. [PDF]
BackgroundSystematic reviews are a cornerstone of evidence-based medicine but are useful only if up-to-date. Methods for detecting signals of when a systematic review needs updating have face validity, but no proposed method has had an assessment of ...
Johnsen, Breanne +3 more
core +1 more source
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
Nefazodone in psychotic unipolar and bipolar depression: A retrospective chart analysis and open prospective study on its efficacy and safety versus combined treatment with amitriptyline and haloperidol [PDF]
Although atypical antipsychotics are on the rise, traditional treatment of psychotic (or delusional) depression mostly includes the addition of classical antipsychotics to antidepressants. As there are only few data supporting this approach compared with
Born, Christoph +4 more
core +1 more source
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar +5 more
wiley +1 more source
Alcohol addiction: a molecular biology perspective. [PDF]
Alcohol misuse represents worldwide an important risk factor for death and disability. Excessive alcohol consumption is widely diffused in different ethnicities and alcohol use is part of the lifestyle of both young and old people.
Ferraguti, Giampiero +2 more
core +1 more source
Background Aims Pharmacokinetic interaction studies typically focus on oral administration, but intravenous (IV) administration bypasses intestinal degradation and hepatic first‐pass metabolism, leading to distinct drug–drug interaction (DDI) magnitude. This study aimed to develop a predictive model for DDIs involving IV‐administered drugs.
Vianney Tuloup +2 more
wiley +1 more source
CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park +2 more
wiley +1 more source

